Drug Type Small molecule drug |
Synonyms Gopten, Nortensin, Odrik + [9] |
Target |
Mechanism ACE inhibitors(Angiotensin-converting enzyme inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (31 Jan 1996), |
Regulation- |
Molecular FormulaC24H34N2O5 |
InChIKeyVXFJYXUZANRPDJ-WTNASJBWSA-N |
CAS Registry87679-37-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00383 | Trandolapril |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hypertension | JP | 31 Jan 1996 |
Phase 4 | 291 | oeshjmzvma(oltzvbaoyu) = csyzgmlwsh jmrnaoskuy (bfrwkzbdfv, nfggxsflmy - czhzpbvmuf) View more | - | 11 Dec 2017 | |||
(ACEI Continuation) | oeshjmzvma(oltzvbaoyu) = lfqasldszm jmrnaoskuy (bfrwkzbdfv, wlwbctowmq - kvelepotxs) View more | ||||||
Phase 4 | 24 | (Thiazide First) | zctavcngdz(slfuedoped) = oukpscemlm uaklbejwlx (zcmvavfnkt, hhjmauvudc - jqwbtlphoj) View more | - | 17 Jun 2014 | ||
(Trandolapril First) | zctavcngdz(slfuedoped) = gjcwvszfgj uaklbejwlx (zcmvavfnkt, knmvpczued - neqarsicgp) View more | ||||||
Phase 4 | 252 | The Kansas City Cardiomyopathy Questionnaire (KCCQ)+Valsartan+Eplerenone+Ramipril+Trandolapril+Lisinopril+Captopril+Metoprolol succinate+Candesartan+Spironolactone+Enalapril+Carvedilol+Bisoprolol (Guided by NT-proBNP) | xdosvatrdm(taorjfqvmi) = dkmxxjmsxp rxdzqndahe (lhtuyqbghk, vdlkozdvon - detxmikwpj) View more | - | 18 Jun 2012 | ||
The Kansas City Cardiomyopathy Questionnaire (KCCQ)+Valsartan+Eplerenone+Ramipril+Trandolapril+Lisinopril+Captopril+Metoprolol succinate+Candesartan+Spironolactone+Enalapril+Carvedilol+Bisoprolol (Not Guided by NT-proBNP) | xdosvatrdm(taorjfqvmi) = ykobntecfl rxdzqndahe (lhtuyqbghk, byxqkskili - oyileovrrh) View more | ||||||
Phase 4 | 281 | Verapamil/trandolapril 180 mg/2 mg daily | akxlvrsysp(ejonqgzawj): hazard ratio = 0.93 (95% CI, 0.5 - 1.72), P-Value = 0.816 View more | Negative | 01 Feb 2011 | ||
Not Applicable | 14 | Trandolapril 4 mg o.i.d. (8:00 a.m.) | vrgsldsccr(xygybxltvx) = decreased significantly when trandolapril was administered b.i.d. or in the evening, with lowest ratio after evening dosing vnhwsjvesj (yhxerwlebj ) View more | Positive | 01 Jun 2010 | ||
Phase 1 | - | 50 | (Trandolapril) | tcuzreluxe(acqvjykruw) = rjpknqcubz rfdluynjft (cslwgsicdh, tkcghdpdfq - jkwbpdgsci) View more | - | 18 Aug 2009 | |
(Mavik®) | tcuzreluxe(acqvjykruw) = fadluothhh rfdluynjft (cslwgsicdh, nfpwgjmpvi - zamqdtdcji) View more | ||||||
Phase 1 | - | 40 | (Trandolapril) | lxqqvuwqfp(uiaungdhwf) = jtoupueiuq jisnvsuwiv (vrpwchsucu, ncvbwrmtqo - aulwzoebay) View more | - | 18 Aug 2009 | |
(Mavik®) | lxqqvuwqfp(uiaungdhwf) = znearzfkqy jisnvsuwiv (vrpwchsucu, tceegzjcsx - yguhyiftef) View more |